MSCL Share Price Performance
Recent MSCL News & Updates
No updates
Satellos Bioscience Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.12
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Satellos Bioscience Inc. Competitors
About MSCL
- Founded
- 2018
- Employees
- 16
- CEO
- WebsiteView website
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Canadian Market Performance
- 7 Days: 0.7%
- 3 Months: 10.9%
- 1 Year: 17.6%
- Year to Date: 10.6%
Over the last 7 days, the market has remained flat, although notably the Healthcare sector gained 4.2% in that time. As for the longer term, the market has risen 18% in the past 12 months. Earnings are forecast to grow by 12% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading